Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-guided Radiotherapy After Chemoimmunotherapy for Locally Advanced ESCC
NCT07721103Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, Paclitaxel Micelles for Injection and Cisplatin micelle injection (HA132) in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Safety and Tolerability Equivalent Major Pathological Response Rate at 1.5 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tislelizumabPaclitaxel Micelles for InjectionCisplatin micelle injection (HA132)
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07721103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07721103.